Quoin Pharmaceuticals Ltd. (QNRX)
QNRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1671502/000110465922045620/0001104659-22-045620-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QNRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2016 |
| SEC CIK | 0001671502 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$21.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.5M |
| Total assets | $9.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $10.1M cash; operating cash flow -$4.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-35 on 2025-04-09 | Source 2025-04-09 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-11-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $309K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$4.9M | -$5.8M | $10.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$5.4M | -$3.1M | $3.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$5.0M | -$4.9M | $3.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$4.3M | -$5.0M | $3.8M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$3.9M | -$2.2M | $1.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$3.7M | -$3.7M | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$3.8M | -$2.6M | $3.8M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$2.3M | -$2.2M | $3.6M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-04 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-10-02 |
Source: SEC EDGAR submissions feed, 587 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.4% |
| 1 month | -10.8% |
| 3 months | -38.8% |
| Year to date | -74.4% |
| 1 year | -72.4% |
| From 52-week high | -83.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KTTA | Pasithea Therapeutics Corp. | $0.5000 | -4.21% | $16.7M |
| LPCN | Lipocine Inc. | $1.66 | -2.92% | $18.4M |
| NCEL | NewcelX Ltd. | $2.75 | +5.36% | $15.9M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier